Small molecule covalent inhibitors of KRASG12C have shown efficacy in animal models and in the clinic.2,3 One of these, sotorasib (AMG 510, LUMAKRASTM), was recently approved for treatment in patients with KRASG12C driven non-small cell lung cancers that are either metastatic or locally advanced.4 Despite these remarkable advances, significant challenges remain for targeting tumors driven by KRAS with non-G12C mutations. Here, KRAS is linked to non-small cell lung carcinoma.